Weekly epidemiological record 1 October 2021 No 39, 2021, 96, 477–484 Report from IACO30: Disruption of ivermectin mass drug administration in the Yanomami focus
Authors: Elizabeth Fitch, Alison Krentel, Kevin Bardosh, Beth Sutherland, Alyssa Jordan, and Margaret Baker The World Health Organization’s 2021-2030 NTD Road Map advocates for
Onchocerciasis: diagnostic target product profile to support preventive chemotherapy. WHO, 2021. Overview Onchocerciasis, also known as river blindness, affects an estimated 21 million people,
Video recordings from “The Power of Partnership: Defeating Onchocerciasis” symposium are ready to view. Featuring 29 speakers from diverse aspects of the campaign, the
Weekly epidemiological record 2 October 2020 No 40, 2019, 484-487 Progress in eliminating onchocerciasis in the WHO Region of the Americas: advances towards transmission
This is footage[1] of microfilariae was captured in a 59-year-old man’s anterior chamber of the eye. The man lives in an onchocerciasis-endemic area in
Parasites Vectors 13, 258 (2020). Published May 15, 2020. Authors: Jérémy T Campillo, Cédric B Chesnais, Sébastien D Pion, Jacques Gardon, Joseph Kamgno, Michel
This short film covers the movement to eliminate onchocerciasis (river blindness) in the central African nation of Cameroon. In French with English subtitles. Follow
Angéline Chebin, a community drug distributor (CDD) in Cameroon, ensures that locals receive their treatments for river blindness. Mrs. Chebin is known for her
Progress report on the elimination of human onchocerciasis, 2018–2019. Weekly Epidemiological Record. WHO, 2019. Overview November 8, 2019 Onchocerciasis is a parasitic infection caused
Weekly epidemiological record 13 September 2019 No. 94 (37): 415 – 419 Progress in eliminating onchocerciasis in the WHO Region of the Americas: doxycycline
River Blindness: The Beginning of the End (2018) From the The Non-Governmental Development Organisation (NGDO) Group for Onchocerciasis Elimination For many individuals and their
Progress report on the elimination of human onchocerciasis, 2017–2018. Weekly Epidemiological Record. WHO, 2018 Overview Onchocerciasis, commonly known as “river blindness”, is a parasitic
Weekly epidemiological record 12 October 2018 No. 93 (41): 541 – 544 Progress towards eliminating onchocerciasis in the WHO Region of the Americas: advances
On June 14, 2018, the US FDA approved moxidectin as a treatment for onchocerciasis (river blindness). We applaud Medicines Development for Global Health (MDGH)
Article on the importance of cross-border issues in onchocerciasis elimination programmes. Bush, Sodahlon, Downs and Mackenzie, International Health, Volume 10, Issue suppl_1, 1 March 2018,
Article on the use of alternative (or complementary) treatment strategies (ATSs) to accelerate the elimination of onchocerciasis. Boussinesq et al., International Health, Volume 10,
Article on eliminating onchocercias as a public health problem in Uganda. Katabarwa et al, International Health, Volume 10, Issue suppl_1, 1 March 2018, Pages
